By Associate Professor Liz Caldon

Journal articles

Holliday H; Yang J; Dodson E; Nikolic I; Kamili A; Wheatley M; Deng N; Alexandrou S; Davis TP; Kavallaris M; Caldon CE; McCarroll J; De Preter K; Mestdagh P; Marshall GM; Simpson KJ; Fletcher J; Swarbrick A, 2024, 'Erratum: miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma (Molecular Therapy (2022) 30(3) (1119–1134), (S1525001622000041), (10.1016/j.ymthe.2022.01.004))', Molecular Therapy, 32, pp. 2031 - 2033, http://dx.doi.org/10.1016/j.ymthe.2024.05.008

Achinger-Kawecka J; Stirzaker C; Portman N; Campbell E; Chia KM; Du Q; Laven-Law G; Nair SS; Yong A; Wilkinson A; Clifton S; Milioli HH; Alexandrou S; Caldon CE; Song J; Khoury A; Meyer B; Chen W; Pidsley R; Qu W; Gee JMW; Schmitt A; Wong ES; Hickey TE; Lim E; Clark SJ, 2024, 'The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer', Nature Structural and Molecular Biology, 31, pp. 498 - 512, http://dx.doi.org/10.1038/s41594-023-01181-7

Phan Z; Ford CE; Caldon CE, 2023, 'DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: A meta-analysis and systematic review', Pharmacological Research, 196, http://dx.doi.org/10.1016/j.phrs.2023.106927

Morra A; Mavaddat N; Muranen TA; Ahearn TU; Allen J; Andrulis IL; Auvinen P; Becher H; Behrens S; Blomqvist C; Bojesen SE; Bolla MK; Brauch H; Camp NJ; Carvalho S; Castelao JE; Cessna MH; Chang-Claude J; Chenevix-Trench G; Sahlberg KK; Børresen-Dale AL; Gram IT; Olsen KS; Engebråten O; Naume B; Geisler J; OSBREAC ; Grenaker Alnæs GI; Czene K; Decker B; Dennis J; Dörk T; Dorling L; Dunning AM; Ekici AB; Eriksson M; Evans DG; Fasching PA; Figueroa JD; Flyger H; Gago-Dominguez M; García-Closas M; Geurts-Giele WRR; Giles GG; Guénel P; Gündert M; Hahnen E; Hall P; Hamann U; Harrington PA; He W; Heikkilä P; Hooning MJ; Hoppe R; Howell A; Humphreys K; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Bennett I; Bogwitz M; Botes L; Brennan M; Brown M; Buckley M; Burke J; Butow P; Caldon L; Campbell I; Cao M; Chakrabarti A; Chauhan D; Chauhan M; Christian A; Cohen P; Colley A; Crook A; Cui J; Courtney E; Cummings M; Dawson SJ; DeFazio A; Delatycki M; Dickson R; Dixon J; Edkins T; Edwards S; Farshid G; Fellows A; Fenton G; Field M; Flanagan J; Fong P; Forrest L; Fox S; French J; Friedlander M; Gaff C, 2023, 'The impact of coding germline variants on contralateral breast cancer risk and survival', American Journal of Human Genetics, 110, pp. 475 - 486, http://dx.doi.org/10.1016/j.ajhg.2023.02.003

Zhou FH; Downton T; Freelander A; Hurwitz J; Caldon CE; Lim E, 2023, 'CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective', Frontiers in Cell and Developmental Biology, 11, http://dx.doi.org/10.3389/fcell.2023.1148792

Aziz D; Lee C; Chin V; Fernandez KJ; Phan Z; Waring P; Caldon CE, 2022, 'High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer', Journal of Pathology: Clinical Research, 8, pp. 355 - 370, http://dx.doi.org/10.1002/cjp2.269

Jahan Z; Benthani FA; Currey N; Parker HW; Dahlstrom JE; Caldon CE; Kohonen-Corish MRJ, 2022, 'MCC Gene Silencing Is a CpG Island Methylator Phenotype-Associated Factor That Predisposes Colon Cancer Cells to Irinotecan and Olaparib', Cancers, 14, http://dx.doi.org/10.3390/cancers14122859

Holliday H; Yang J; Dodson E; Nikolic I; Kamili A; Wheatley M; Deng N; Alexandrou S; Davis TP; Kavallaris M; Caldon CE; McCarroll J; De Preter K; Mestdagh P; Marshall GM; Simpson KJ; Fletcher J; Swarbrick A, 2022, 'miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma', Molecular Therapy, 30, pp. 1119 - 1134, http://dx.doi.org/10.1016/j.ymthe.2022.01.004

Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Phan Z; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell DD; Serra V; Waring P; Lim E; Caldon CE, 2021, 'Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition', npj Breast Cancer, 7, http://dx.doi.org/10.1038/s41523-021-00312-x

Murphy KJ; Reed DA; Vennin C; Conway JRW; Nobis M; Yin JX; Chambers CR; Pereira BA; Lee V; Filipe EC; Trpceski M; Ritchie S; Lucas MC; Warren SC; Skhinas JN; Magenau A; Metcalf XL; Stoehr J; Major G; Parkin A; Bidanel R; Lyons RJ; Zaratzian A; Tayao M; Da Silva A; Abdulkhalek L; Gill AJ; Johns AL; Biankin AV; Samra J; Grimmond SM; Chou A; Goetz JG; Samuel MS; Lyons JG; Burgess A; Caldon CE; Horvath LG; Daly RJ; Gadegaard N; Wang Y; Sansom OJ; Morton JP; Cox TR; Pajic M; Herrmann D; Timpson P, 2021, 'Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status', Science Advances, 7, http://dx.doi.org/10.1126/sciadv.abh0363

Du Q; Smith GC; Luu PL; Ferguson JM; Armstrong NJ; Caldon CE; Campbell EM; Nair SS; Zotenko E; Gould CM; Buckley M; Chia KM; Portman N; Lim E; Kaczorowski D; Chan CL; Barton K; Deveson IW; Smith MA; Powell JE; Skvortsova K; Stirzaker C; Achinger-Kawecka J; Clark SJ, 2021, 'DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity', Cell Reports, 36, http://dx.doi.org/10.1016/j.celrep.2021.109722

Floerchinger A; Murphy KJ; Latham SL; Warren SC; McCulloch AT; Lee YK; Stoehr J; Mélénec P; Guaman CS; Metcalf XL; Lee V; Zaratzian A; Da Silva A; Tayao M; Rolo S; Phimmachanh M; Sultani G; McDonald L; Mason SM; Ferrari N; Ooms LM; Johnsson AKE; Spence HJ; Olson MF; Machesky LM; Sansom OJ; Morton JP; Mitchell CA; Samuel MS; Croucher DR; Welch HCE; Blyth K; Caldon CE; Herrmann D; Anderson KI; Timpson P; Nobis M, 2021, 'Optimizing metastatic-cascade-dependent Rac1 targeting in breast cancer: Guidance using optical window intravital FRET imaging', Cell Reports, 36, http://dx.doi.org/10.1016/j.celrep.2021.109689

Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD, 2021, 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27, pp. 310 - 320, http://dx.doi.org/10.1038/s41591-020-01168-7

Achinger-Kawecka J; Valdes-Mora F; Luu PL; Giles KA; Caldon CE; Qu W; Nair S; Soto S; Locke WJ; Yeo-Teh NS; Gould CM; Du Q; Smith GC; Ramos IR; Fernandez KF; Hoon DS; Gee JMW; Stirzaker C; Clark SJ; Valdes Mora F, 2020, 'Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer', Nature Communications, 11, pp. 320, http://dx.doi.org/10.1038/s41467-019-14098-x

Kramer I; Hooning MJ; Mavaddat N; Hauptmann M; Keeman R; Steyerberg EW; Giardiello D; Antoniou AC; Pharoah PDP; Canisius S; Abu-Ful Z; Andrulis IL; Anton-Culver H; Aronson KJ; Augustinsson A; Becher H; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Bogdanova NV; Bojesen SE; Bolla MK; Bonanni B; Brauch H; Bremer M; Brucker SY; Burwinkel B; Castelao JE; Chan TL; Chang-Claude J; Chanock SJ; Chenevix-Trench G; Choi JY; Clarke CL; Børresen-Dale AL; Sahlberg K; Ottestad L; Kåresen R; Schlichting E; Holmen MM; Sauer T; Haakensen V; Engebråten O; Naume B; Fosså A; Kiserud C; Reinertsen K; Helland Å; Riis M; Geisler J; Alnæs GG; Collée JM; Couch FJ; Cox A; Cross SS; Czene K; Daly MB; Devilee P; Dörk T; dos-Santos-Silva I; Dunning AM; Dwek M; Eccles DM; Evans DG; Fasching PA; Flyger H; Gago-Dominguez M; García-Closas M; García-Sáenz JA; Giles GG; Goldgar DE; González-Neira A; Haiman CA; Håkansson N; Hamann U; Hartman M; Heemskerk-Gerritsen BAM; Hollestelle A; Hopper JL; Hou MF; Howell A; Marsh D; Scott R; Baxter R; Yip D; Carpenter J; Davis A; Pathmanathan N; Simpson P; Graham JD; Sachchithananthan M; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Bennett I; Bogwitz M, 2020, 'Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk', American Journal of Human Genetics, 107, pp. 837 - 848, http://dx.doi.org/10.1016/j.ajhg.2020.09.001

Elizabeth Caldon C; Caldon L, 2020, 'Friends and foes: Our evolving understanding of the link between Fbxw7 and p53 in cancer', Neoplasia (United States), 22, pp. 659 - 660, http://dx.doi.org/10.1016/j.neo.2020.07.007

Burgess A; Caldon CE, 2020, 'Editorial: Proceedings From ACCM19: Cell Cycle, DNA Damage Response and Telomeres', Frontiers in Cell and Developmental Biology, 8, http://dx.doi.org/10.3389/fcell.2020.00805

Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', Breast Cancer Research, 22, pp. 87, http://dx.doi.org/10.1186/s13058-020-01318-2

Lee C; Fernandez KJ; Alexandrou S; Marcelo Sergio C; Deng N; Rogers S; Burgess A; Elizabeth Caldon C, 2020, 'Cyclin E2 promotes whole genome doubling in breast cancer', Cancers, 12, pp. 1 - 19, http://dx.doi.org/10.3390/cancers12082268

Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, 2020, 'MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer', , http://dx.doi.org/10.1101/2020.06.09.140921

Castillo L; Young AIJ; Mawson A; Schafranek P; Steinmann AM; Nessem D; Parkin A; Johns A; Chou A; Law AMK; Lucas MC; Murphy KJ; Deng N; Gallego-Ortega D; Caldon CE; Timpson P; Pajic M; Ormandy CJ; Oakes SR, 2020, 'MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma', Oncogene, 39, pp. 1821 - 1829, http://dx.doi.org/10.1038/s41388-019-1091-0

Tadesse S; Anshabo AT; Portman N; Lim E; Tilley W; Caldon CE; Wang S, 2020, 'Targeting CDK2 in cancer: challenges and opportunities for therapy', Drug Discovery Today, 25, pp. 406 - 413, http://dx.doi.org/10.1016/j.drudis.2019.12.001

Milioli HH; Alexandrou S; Lim E; Caldon CE, 2020, 'Cyclin E1 and cyclin E2 in ER+ breast cancer: Prospects as biomarkers and therapeutic targets', Endocrine-Related Cancer, 27, pp. R93 - R112, http://dx.doi.org/10.1530/ERC-19-0501

Li A; Geyer FC; Blecua P; Lee JY; Selenica P; Brown DN; Pareja F; Lee SSK; Kumar R; Rivera B; Bi R; Piscuoglio S; Wen HY; Lozada JR; Gularte-Mérida R; Cavallone L; Aghmesheh M; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Blackburn A; Bogwitz M; Brown M; Burgess M; Burke J; Butow P; Caldon L; Campbell I; Christian A; Clarke C; Cohen P; Crook A; Cui J; Cummings M; Dawson SJ; De Fazio A; Delatycki M; Dobrovic A; Dudding T; Duijf P; Edkins E; Edwards S; Farshid G; Fellows A; Field M; Flanagan J; Fong P; Forbes J; Forrest L; Fox S; French J; Friedlander M; Ortega DG; Gattas M; Giles G; Gill G; Gleeson M; Greening S; Haan E; Harris M; Hayward N; Hickie I; Hopper J; Hunt C; James P; Jenkins M; Kefford R; Kentwell M; Kirk J; Kollias J; Lakhani S; Lindeman G; Lipton L; Lobb L; Lok S; Macrea F; Mann G; Marsh D; McLachlan SA; Meiser B; Milne R; Nightingale S; O’Connell S; Pachter N; Patterson B; Phillips K; Saleh M; Salisbury E; Saunders C; Saunus J; Scott C; Scott R; Sexton A; Shelling A; Simpson P; Spigelman A; Spurdle M; Stone J, 2019, 'Homologous recombination DNA repair defects in PALB2-associated breast cancers', npj Breast Cancer, 5, http://dx.doi.org/10.1038/s41523-019-0115-9

Du Q; Bert SA; Armstrong NJ; Caldon CE; Song JZ; Nair SS; Gould CM; Luu PL; Peters T; Khoury A; Qu W; Zotenko E; Stirzaker C; Clark SJ, 2019, 'Replication timing and epigenome remodelling are associated with the nature of chromosomal rearrangements in cancer', Nature Communications, 10, http://dx.doi.org/10.1038/s41467-019-08302-1

Figlioli G; Bogliolo M; Catucci I; Caleca L; Lasheras SV; Pujol R; Kiiski JI; Muranen TA; Barnes DR; Dennis J; Michailidou K; Bolla MK; Leslie G; Aalfs CM; Balleine R; Baxter R; Braye S; Carpenter J; Dahlstrom J; Forbes J; Lee CS; Marsh D; Morey A; Pathmanathan N; Scott R; Simpson P; Spigelman A; Wilcken N; Yip D; Zeps N; Adank MA; Adlard J; Agata S; Cadoo K; Agnarsson BA; Ahearn T; Aittomäki K; Ambrosone CB; Andrews L; Anton-Culver H; Antonenkova NN; Arndt V; Arnold N; Aronson KJ; Arun BK; Asseryanis E; Auber B; Auvinen P; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Barwell J; Beane Freeman LE; Beauparlant CJ; Beckmann MW; Behrens S; Benitez J; Berger R; Bermisheva M; Blanco AM; Blomqvist C; Bogdanova NV; Bojesen A; Bojesen SE; Bonanni B; Borg A; Brady AF; Brauch H; Brenner H; Brüning T; Burwinkel B; Buys SS; Caldés T; Caliebe A; Caligo MA; Campa D; Campbell IG; Canzian F; Castelao JE; Chang-Claude J; Chanock SJ; Claes KBM; Clarke CL; Collavoli A; Conner TA; Cox DG; Cybulski C; Czene K; Daly MB; de la Hoya M; Devilee P; Diez O; Ding YC; Dite GS; Ditsch N; Domchek SM; Dorfling CM; dos-Santos-Silva I; Durda K, 2019, 'The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer', npj Breast Cancer, 5, http://dx.doi.org/10.1038/s41523-019-0127-5

Lee CS; Rogers S; Fernandez K; Alexandrou S; Deng N; Sergio CM; Kulkarni A; Gugasyan L; Musgrove EA; Deans AJ; Burgess A; Caldon CE, 2019, 'Mechanisms underlying uncontrolled genome doubling in breast cancer', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p008

Tadesse S; Caldon EC; Tilley W; Wang S, 2019, 'Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update', Journal of Medicinal Chemistry, 62, pp. 4233 - 4251, http://dx.doi.org/10.1021/acs.jmedchem.8b01469

Chia KM; Milioli H; Portman N; Laven-Law G; Coulson R; Yong A; Segara D; Parker A; Caldon CE; Deng N; Swarbrick A; Tilley WD; Hickey TE; Lim E, 2019, 'Non-canonical AR activity facilitates endocrine resistance in breast cancer', Endocrine-Related Cancer, 26, pp. 251 - 264, http://dx.doi.org/10.1530/ERC-18-0333

Caldon CE; Burgess A, 2019, 'Label free, quantitative single-cell fate tracking of time-lapse movies', MethodsX, 6, pp. 2468 - 2475, http://dx.doi.org/10.1016/j.mex.2019.10.014

Currey N; Jahan Z; Caldon CE; Tran PN; Benthani F; De Lacavalerie P; Roden DL; Gloss BS; Campos C; Bean EG; Bullman A; Reibe-Pal S; Dinger ME; Febbraio MA; Clarke SJ; Dahlstrom JE; Kohonen-Corish MRJ, 2019, 'Mouse Model of Mutated in Colorectal Cancer Gene Deletion Reveals Novel Pathways in Inflammation and Cancer', Cellular and Molecular Gastroenterology and Hepatology, 7, pp. 819 - 839, http://dx.doi.org/10.1016/j.jcmgh.2019.01.009

Portman N; Alexandrou S; Carson E; Wang S; Lim E; Caldon CE, 2019, 'Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer', Endocrine-Related Cancer, 26, pp. R15 - R30, http://dx.doi.org/10.1530/ERC-18-0317

Alexandrou S; George SM; Ormandy CJ; Lim E; Oakes SR; Elizabeth Caldon C, 2019, 'The proliferative and apoptotic landscape of basal-like breast cancer', International Journal of Molecular Sciences, 20, http://dx.doi.org/10.3390/ijms20030667

Aziz D; Lee C; Chin V; Fernandez K; Etemadmoghadam D; Bowtell D; Waring PM; Caldon CE, 2019, 'Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)', Annals of Oncology, 30, pp. ix86 - ix86, http://dx.doi.org/10.1093/annonc/mdz426.029

Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; Bowtell D; Waring P, 2018, '19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes', Gynecologic Oncology, 151, pp. 327 - 336, http://dx.doi.org/10.1016/j.ygyno.2018.08.039

Rogers S; McCloy RA; Parker BL; Gallego-Ortega D; Law AMK; Chin VT; Conway JRW; Fey D; Millar EKA; O’Toole S; Deng N; Swarbrick A; Chastain PD; Cesare AJ; Timpson P; Caldon CE; Croucher DR; James DE; Watkins DN; Burgess A, 2018, 'MASTL overexpression promotes chromosome instability and metastasis in breast cancer', Oncogene, 37, pp. 4518 - 4533, http://dx.doi.org/10.1038/s41388-018-0295-z

Conway JRW; Warren SC; Herrmann D; Murphy KJ; Cazet AS; Vennin C; Shearer RF; Killen MJ; Magenau A; Mélénec P; Pinese M; Nobis M; Zaratzian A; Boulghourjian A; Da Silva AM; del Monte-Nieto G; Adam ASA; Harvey RP; Haigh JJ; Wang Y; Croucher DR; Sansom OJ; Pajic M; Caldon CE; Morton JP; Timpson P; del Monte Nieto G; Gallego-Ortega D, 2018, 'Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer', Cell Reports, 23, pp. 3312 - 3326, http://dx.doi.org/10.1016/j.celrep.2018.05.038

Law AMK; Yin JXM; Castillo L; Young AIJ; Piggin C; Rogers S; Caldon CE; Burgess A; Millar EKA; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR, 2017, 'Andy's Algorithms: New automated digital image analysis pipelines for FIJI', Scientific Reports, 7, http://dx.doi.org/10.1038/s41598-017-15885-6

Rogers S; Fey D; McCloy RA; Parker BL; Mitchell NJ; Payne RJ; Daly RJ; James DE; Caldon CE; Watkins DN; Croucher DR; Burgess A, 2016, 'PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells', Journal of Cell Science, 129, pp. 1340 - 1354, http://dx.doi.org/10.1242/jcs.179754

Caldon CE, 2016, 'Cdk2 regulates metastasis suppressor BRMS1', Cell Cycle, 15, pp. 779 - 780, http://dx.doi.org/10.1080/15384101.2015.1136521

Susanto JM; Colvin EK; Pinese M; Chang DK; Pajic M; Mawson A; Caldon CE; Musgrove EA; Henshall SM; Sutherland RL; Biankin AV; Scarlett CJ, 2015, 'The epigenetic agents suberoylanilide hydroxamic acid and 5-AZA-2′ deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo', International Journal of Oncology, 46, pp. 2223 - 2230, http://dx.doi.org/10.3892/ijo.2015.2894

Loh SF; Cooper C; Selinger CI; Barnes EH; Chan C; Carmalt H; West R; Gluch L; Beith JM; Caldon CE; O'Toole S, 2015, 'Cell cycle marker expression in benign and malignant intraductal papillary lesions of the breast', Journal of Clinical Pathology, 68, pp. 187 - 191, http://dx.doi.org/10.1136/jclinpath-2014-202331

Rogers S; Gloss BS; Lee CS; Sergio CM; Dinger ME; Musgrove EA; Burgess A; Caldon CE, 2015, 'Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells', Cell Division, 10, pp. 1, http://dx.doi.org/10.1186/s13008-015-0007-9

McCloy RA; Rogers S; Caldon CE; Lorca T; Castro A; Burgess A, 2014, 'Partial inhibition of Cdk1 in G2 phase overrides the SAC and decouples mitotic events', Cell Cycle, 13, pp. 1400 - 1412, http://dx.doi.org/10.4161/cc.28401

Caldon CE, 2014, 'Estrogen signaling and the dna damage response in hormone dependent breast cancers', Frontiers in Oncology, 4 MAY, http://dx.doi.org/10.3389/fonc.2014.00106

Stone A; Cowley MJ; Valdes-Mora F; McCloy RA; Sergio CM; Gallego-Ortega D; Caldon CE; Ormandy CJ; Biankin AV; Gee JMW; Nicholson RI; Print CG; Clark SJ; Musgrove EA, 2013, 'BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer', Molecular Cancer Therapeutics, 12, pp. 1874 - 1885, http://dx.doi.org/10.1158/1535-7163.MCT-13-0012

Caldon CE; Sergio CM; Burgess A; Deans AJ; Sutherland RL; Musgrove EA, 2013, 'Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1', Cell Cycle, 12, pp. 606 - 617, http://dx.doi.org/10.4161/cc.23512

Ortiz-padilla C; Gallego-ortega D; Browne B; Hochgrafe F; Caldon CE; Lyons R; Croucher DR; Rickwood D; Ormandy CJ; Brummer T; Daly RJ, 2013, 'Functional characterization of cancer-associated Gab1 mutations', Oncogene, 32, pp. 2696 - 2702, http://dx.doi.org/10.1038/onc.2012.271

Caldon CE; Sergio CM; Kang J; Muthukaruppan A; Boersma MN; Stone A; Barraclough J; Lee CS; Black MA; Miller LD; Gee JM; Nicholson RI; Sutherland RL; Print CG; Musgrove EA, 2012, 'Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells', MOLECULAR CANCER THERAPEUTICS, 11, pp. 1488 - 1499, http://dx.doi.org/10.1158/1535-7163.MCT-11-0963

Caldon CE; Sergio CM; Kang JW; Muthukaruppan A; Boersma M; Stone A; Barraclough J; Lee CS; Black MJ; Miller LA; Gee JMW; Robert i nicholson RI; Sutherland RL; Print C; Musgrove EA, 2012, 'Cyclin E2 overexpression is associated with endocrine resistance but not insensivity to CDK2 inhibition in human breast cancer cells', Molecular Cancer Therapeutics, 11, pp. 1488 - 1499, http://dx.doi.org/10.1158/1535-7163.MCT-11-0963

Back to profile page